In addition to these widely used AOMs, Exenatide, one of the earliest GLP-1 RAs approved by the FDA and EMA for T2DM management, is not indicated for weight management but remains clinically relevant, particularly in older adults with comorbid obesity and T2DM, given its long-term clinical experience and established tolerability profile [26,27,28]
STEP-5 followed participants for 104 weeks and reported sustained 15.2% mean weight loss, showing durability of effect [5]
If you experience nausea, muscle weakness, or metabolic stalling despite adherence, discuss stopping the supplement with your provider
The first study (2023) evaluated 7,051 patients undergoing TKA who were prescribed semaglutide preoperatively, comparing them to a matched control group of 34,524 non-users
Using it is unlikely to provide the appetite suppression you need and significantly increases the risk of site infections
et al., 2022)